{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luo YH"],"funding":["Ministry of Science and Technology, Taiwan","Ministry of Science and Technology, Taiwan (TW)","Mayo Foundation for Medical Education and Research","NIA NIH HHS","Taipei Veterans General Hospital","Taipei Veterans General Hospital (TW)","Ministry of Health and Welfare","NCI NIH HHS","National Institutes of Health","Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program","National Institute on Aging","NIH HHS"],"pagination":["2099-2114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9945911"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["148(8)"],"pubmed_abstract":["<h4>Background</h4>The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice.<h4>Patients and methods</h4>417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed.<h4>Results</h4>Higher risk of death was found in EGFR-mutant patients with age ≥ 65 years, non-adenocarcinoma, no surgery or radiation, non-exon 19 deletion/exon 21 L858R, higher ECOG PS (2-4), PD-L1 expression ≥ 50%, and bone/liver/adrenal metastasis (all p < 0.05). Osimertinib as ≥ second-line TKI in patients with/without identification of T790M revealed lower risk of death com"],"journal":["Journal of cancer research and clinical oncology"],"pubmed_title":["Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation."],"pmcid":["PMC9945911"],"funding_grant_id":["MOHW109-TDU-B-211-134019","R01 CA080127","R03 CA077118","108-2628-B-075-007 and 109-2628-B-075-023","R33 AG058738","108-V-A-012","V108E-006-3[109] and V109C-123","R01 AG052425","R01 AG034676","R01 AG034676 and R01 AG052425","R03 CA77118, R01 CA80127 and R01 CA84354","R01 CA084354"],"pubmed_authors":["Liu H","Li Y","Yang Y","Leventakos K","Peikert T","Yang P","Wampfler JA","Tazelaar HD","Liu D","Luo YH","Chen YM","Chiou SH"],"additional_accession":[]},"is_claimable":false,"name":"Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.","description":"<h4>Background</h4>The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice.<h4>Patients and methods</h4>417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed.<h4>Results</h4>Higher risk of death was found in EGFR-mutant patients with age ≥ 65 years, non-adenocarcinoma, no surgery or radiation, non-exon 19 deletion/exon 21 L858R, higher ECOG PS (2-4), PD-L1 expression ≥ 50%, and bone/liver/adrenal metastasis (all p < 0.05). Osimertinib as ≥ second-line TKI in patients with/without identification of T790M revealed lower risk of death com","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-21T16:12:47.931Z","creation":"2025-04-21T16:12:47.931Z"},"accession":"S-EPMC9945911","cross_references":{"pubmed":["34436667"],"doi":["10.1007/s00432-021-03766-5"]}}